Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

Seattle Genetics is staffing up with eyes on a big year

Seattle Genetics is looking to recruit roughly 100 new workers throughout its operations, the company said, accelerating its pipeline of armed antibody candidates.

Sanofi dumps an ImmunoGen cancer drug as it scales back in oncology

Sanofi is again trimming its oncology pipeline, walking away from an armed-antibody cancer treatment licensed from ImmunoGen as it reshapes its approach to the field.

Biogen blueprints a big Phase III effort for its Alzheimer's hopeful

Riding high on some promising Phase I data, Biogen has mapped out a big late-stage program for its Alzheimer's disease treatment, making a risky bet that it can reverse decades of failure in the field.

AstraZeneca lends its oncology star to Celgene and recruits Innate in a PD-L1 deal spree

AstraZeneca signed a pair of agreements centered on its most prized cancer therapy, selling a stake to the hematology experts at Celgene and buying the rights to a complementary treatment from Innate Pharma.

Juno and AstraZeneca pair two hot immunotherapies in new cancer study

Juno Therapeutics and AstraZeneca are joining forces to test their respective cancer treatments in tandem, combining newfangled therapies that promise to use the immune system to combat tumors.

Third Rock's Jounce bags $56M to hit the gas in immuno-oncology

While Merck and Bristol-Myers Squibb grab global headlines with treatments designed to make it harder for cancer to hide from the immune system, Cambridge, MA's Jounce Therapeutics is coming at it from the other end, crafting a therapy that revs up the body's natural defenses to attack tumors. And the promise of that idea helped the biotech rope in a massive $56 million B round, cash that will help get its top prospect into clinical trials.

MaxCyte buys into CAR-T with Johns Hopkins partnership

Maryland biotech MaxCyte is delving into the world of CAR-T treatments for cancer, teaming up with Johns Hopkins University on a preclinical program.

Astellas dives into immuno-oncology with a sweeping biotech deal

Japanese pharma giant Astellas is entering the booming field of immuno-oncology, pairing up with Cambridge, MA's Potenza Therapeutics to work on a wide variety of treatments that use the body's natural defenses to combat cancer.

Allied Minds' SciFluor banks $30M to get into the clinic

SciFluor Life Sciences, a graduate of the Allied Minds startup factory, raised $30 million to get its fluorine-based candidates into clinical development.

Biogen gives Roche 'renewed confidence' in its own failed Alzheimer's drugs

Biogen turned heads around the industry last month with early data in which its plaque-destroying Alzheimer's treatment had a significant effect on patients' cognition, bucking a vexing trend for such antibodies. Among those paying close attention was Roche, which is now re-examining a pair of once-failed treatments.